Dynamics of colistin and tobramycin resistance among Enterobacter cloacae during prolonged use of selective decontamination of the digestive tract

Table 2 Incidence of resistant E. cloacae in ICU 1 and 2

	Selection	ICU 1		ICU 2		Period
		All admissions	Admissions > 48 h	All admissions	Admissions > 48 h
Admissions (n)	All	9418	2731	3624	884	1 Jan 2007–1 Nov 2014
Patients (n)	All	8073	2301	3257	836	1 Jan 2007–1 Nov 2014
On admission	MREb	58^a		25^a		1 Jan 2007–1 Nov 2014
Acquisitions (n)	MREb	134		20		1 Jan 2007–1 Nov 2014
Mean incidence (acquisitions/DAR)	MREb	4.60 (69/14977)		1.85 (6/3248)		1 Jan 2011–1 Nov 2014
	Tobramycin I or R	4.95 (130/26265)		2.74 (20/7312)		1 Jan 2007–1 Nov 2014
	Colistin R	5.02 (81/16139)		2.28 (10/4386)		1 Jan 2010–1 Nov 2014
	ESBL production	4.64 (58/12489)		1.88 (6/3200)		1 Jan 2011–1 Nov 2014

DAR days at risk, ESBL extended-spectrum beta-lactamase, I intermediate, ICU intensive care unit, MREb extended-spectrum beta-lactamase production and/or tobramycin non-susceptible and/or colistin-resistant, n number, R resistant. Colistin susceptibility was documented since December 2009 and presence of ESBL since January 2011
^aThese numbers include patients transmitted between the two ICUs. In total in 61 ICU admissions MREb was detected before or on admission

ISSN: 2047-2994